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Abstract
Background: To study the effects of Beta-blockers during Dobutamine Stress Echocardiography
(DSE) comparing the hemodynamic benefits of an early administration of atropine in patients taking
or not Beta-blockers.
Methods:  One hundred and twenty-one patients were submitted to dobutamine stress
echocardiography for the investigation of myocardial ischemia. The administration of atropine was
randomized into two groups: A or B (early protocol when atropine was administered at 10 and 20
mcg/kg/min of dobutamine, respectively) and C (standard protocol with atropine at 40 mcg/kg/min
of dobutamine). Analysis of the effects of Beta-blockers was done regarding the behavior pattern
of heart rate and blood pressure, test time, number of conclusive and inconclusive (negative sub-
maximum test) results, total doses of atropine and dobutamine, and general complications.
Results: Beta-blocked patients who received early atropine (Group A&B) had a significantly lower
double product (p = 0.008), a higher mean test time (p = 0.010) and required a higher dose of
atropine (p = 0.0005) when compared to the patients in this group who were not Beta-blocked.
The same findings occurred in the standard protocol (Group C), however the early administration
of atropine reduced test time both in the presence and absence of this therapy (p = 0.0001). The
patients with Beta-blockers in Group A&B had a lower rate of inconclusive tests (26%) compared
to those in Group C (40%). Complications were similar in both groups.
Conclusion:  The chronotropic response during dobutamine stress echocardiography was
significantly reduced with the use of Beta-blockers. The early administration of atropine optimized
the hemodynamic response, reduced test time in patients with or without Beta-blockers and
reduced the number of inconclusive tests in the early protocol.
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Background
The beta receptors are distributed in the heart leading to
an increase of the inotropism and chronotropism. They
are found in the smooth muscle (vascular and bronchial)
causing dilatation and relaxation of these structures, and
a considerable number is also found in the cardiac muscle
exerting positive inotropic and chronotropic influence
[1]. By definition the Beta-blockers are substances which
antagonize in a specific, competitive and reversible man-
ner the action of the endogenous or exogenous catecho-
lamines in the beta adrenergic receptors. Thus, the blocker
occupies the same receptor site as the agonist, reducing its
response [2].
Since these agents are often administered to patients
referred to stress echocardiography and are not inter-
rupted before the test, information about the effects of
beta-adrenergic blocking on the physiological response of
a dobutamine echocardiogram is important.
Previous studies [3] associated atropine to the dob-
utamine echocardiogram in an attempt to provide a more
effective strategy to increase heart rate (HR) with the
resulting increase of oxygen consumption by the myocar-
dium. The authors concluded that after the addition of
atropine there was an increase in the sensitivity of the test.
From then on, the dobutamine-atropine protocol became
known as a safe method with excellent diagnostic accu-
racy [4-6]. The co-administration of the atropine sulphate
became popular in the Beta-blockers era, as the anti-
angina drugs pronouncedly reduce the sensitivity of the
stress echocardiogram, both with dipyridamole [6] and
dobutamine [7]. The same does not seem to occur in the
dobutamine-atropine stress echocardiography. A plausi-
ble explanation is the fact that the atropine may compen-
sate the chronotropic deficit caused by the Beta-blockers
[7].
Beta-blockers may improve or even prevent stress induced
wall abnormalities [8,9], implying in a decrease of the
ischemic response. As a result, the failure in obtaining an
adequate HR which allows for a diagnostic test (conclu-
sive) reduces the precision of the method and seems not
to correspond to the plasmatic dose of dobutamine,
whose seric level shows a dose-effect relation [10].
The value of the dobutamine-atropine early protocol
among patients, Beta-blocked or not, is still speculative.
Therefore our objective was to study the influence of Beta-
blockers in the early and standard protocols, and compare
the potential hemodynamic benefits of the early adminis-
tration of atropine among patients taking Beta-blockers or
not.
Methods
One hundred and twenty-one consecutive patients exam-
ined and referred to DSE were studied during a one year
period to evaluate coronary artery disease (CAD).
The patients were randomly divided into Groups A, B and
C, where Groups A and B were considered belonging to
the early protocol (with atropine administration at 10 and
20 mcg/kg/min of dobutamine, respectively) and group C
belonging to the standard protocol (atropine at 40 mcg/
kg/min of dobutamine).
We have previously shown the feasibility and accuracy of
early protocol of administration of atropine during dob-
utamine stress echocardiography [11]. When compared to
the standard one, the early protocol is faster and diagnos-
tically more accurate [11].
Patients with counter-indication for the test were excluded
from this study according to exclusion criteria such as:
patients with acute myocardium infarction ≤ 10 days, his-
tory of angina < 48 hours and investigation of myocardial
viability.
Demographic characteristics, risk factors, use of medica-
tion, and ECG, ECHO & angiographic data from total
sample are shown on Table 1.
The present study was approved by the Ethical and
Research Committee of the hospital and patients'
informed consent was obtained.
The left ventricle was divided into 16 segments [12]. Each
segment was described as: normal, hypokinetic, akinetic
or dyskinetic according to the American Society of
Echocardiography.
We considered inconclusive tests those where HR was
lower than 85% of the maximum expected at the end of
the protocol (negative sub-maximum test).
During the exam a 3-lead ECG was maintained, as well as
continuous monitoring of HR and blood pressure at the
end of each stage, before and after the administration of
atropine.
Two kinds of equipment were employed in this study: a
HDI 5000 from ATL (digitalization – "Image View"), and
a Sonos 5500 from HP, both with 4,0 MHz transducers.
Statistical analysis
The X2 test or the Fisher exact tests were used for the com-
parison of proportions between continuous variables. The
Student t test was applied for independent samples to
compare the means between the two groups as well as theCardiovascular Ultrasound 2006, 4:30 http://www.cardiovascularultrasound.com/content/4/1/30
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Mann-Whitney test (non-parametric test) whenever the
variable did not present normal distribution.
The Analysis of Variance (ANOVA) was used to compare
the means between the groups when all three groups had
to be analyzed. The Analysis of Variance of Kruskal-Wallis
(non-parametric test) was used for the comparative anal-
ysis of variables which did not present a normal distribu-
tion.
The adopted criteria for determining any significance was
set at 5%, in other words, whenever the value of p of the
statistical analysis was ≤ 0.05.
Results
Of the total sample (n = 121), 76 patients received early
atropine (Groups A & B). Not all 45 patients in the stand-
ard protocol group received atropine, since this depended
on the end-point of the test.
Of the total number of patients studied, 45% were taking
Beta-blockers and there was no difference among the
groups regarding the use of this drug.
In patients taking Beta-blockers, inconclusive results pre-
dominated in the standard protocol group (40%) when
compared to the early protocol (26%) as shown in the Fig-
ures 1 and 2.
Behavior of HR with or without Beta-blockers may be seen
in Figures 3 and 4. Behavior of SBP with or without Beta-
blockers may be seen in Figures 5 and 6.
Descriptive analysis of ATR dose, test time, HR × SBP and
DOB dose, according to Beta-blocker, for groups A & B
(early protocol) or group C (standard protocol) can be
seen in Tables 2 and 3, respectively.
Table 4 shows the level of significance of the statistical
analysis for results, complications and interruption of test.
We observed that patients not taking Beta-blockers pre-
sented a significantly higher proportion of negative results
than those taking Beta-blockers. On the other hand,
patients taking Beta-blockers showed significantly higher
positive or inconclusive results compared to the patients
without Beta-blockers. There was no difference between
early and standard protocols in relation to complications.
Table 5 shows the test accuracy for the early (A+B) and
standard (C) protocol in patients who were submitted to
angiography.
Discussion
Many patients did not reach the desired HR during DSE.
Possible explanations described in literature may justify
this fact such as, chronotropic incompetence [13], para-
dox sinus deceleration [14], and the Bezold-Jarisch reflex
Table 1: Demographic characteristics, risk factors, medication, and ECG, Echo and Angiographic data according to Groups.
VARIABLES GROUP A (n = 41) GROUP B (n = 35) GROUP C (n = 45) p value
Age 60,8 +/- 11 59,6 +/- 12 54 +/- 12 0,038
Gender (male %) 51,2 54,2 65 0,47
Reasons for test:
-Investigation for CAD (%) 46 66 55 0,23
-Evaluation of known CAD (%) 54 34 45 0,23
H y p e r t e n s i o n  ( % ) 6 16 24 5 0 , 6 1
Diabetes (%) 20 20 21 0,98
Hyperlipemia (%) 46 62 35 0,10
Family history for CAD (%) 49 60 46 0,49
S m o k i n g  ( % ) 2 93 12 4 0 , 8 0
Obesity (%) 36 28 45 0,40
Use of Beta-blocker (%) 49 54 45 0,74
Use of Calcium blocker (%) 12 20 10 0,48
Altered baseline ECG (%) 38 39 41 0,97
Altered baseline Echo (%) 41 37 42 0,87
Normal LV function (%) 66 86 65 0,097
Previous angiography (%) 46 40 36 0,68
Previous PTCA (%) 19 12 10 0,60
Previous CABG (%) 17 17 10 0,69
CAD = coronary artery disease, ECG = electrocardiogram,
Echo = echocardiogram, LV = left ventricle, PTCA = percutaneous transluminal coronary angioplasty,
CABG = coronary artery bypass graft.Cardiovascular Ultrasound 2006, 4:30 http://www.cardiovascularultrasound.com/content/4/1/30
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[15,16]. However, the most common reason was the use
of Beta-adrenergic blockers.
In a study conducted by Weissman et al.[9], the authors
found evidence that the hemodynamic parameters such
as: HR, arterial pressure, area of left ventricle and coronary
blood flow increased more slowly and to a lower degree
in the presence of Beta-blockers, which resulted in a pro-
longed test time. The necessary dobutamine dose in the
Beta-blocked group was also significantly higher than in
the group with no adrenergic blocking [9].
Therefore it is important to observe the accuracy of the test
during the use of Beta-blockers. Sawada et al.[17] demon-
strated that the sensitivity was similar between patients
who were Beta-blocked and those who were not, however
the authors suggest a possible bias in the selection of
patients (more severe CAD in Beta-blocked patients).
Other authors believe the low HR peak in the presence of
Beta-blockers adversely affects the sensitivity of the
method [9,18], thus recommending the increase of the
dobutamine dose or the assistance of other drugs such as
atropine [19-21].
In the current analysis, a significant decrease in the total
dose of dobutamine was detected after early administra-
tion of atropine and there was no need to increase the
dose of cholinergic antagonist. Besides, the hemodynamic
response during the dobutamine test was pronouncedly
reduced in the presence of Beta-blocking therapy, most
Behavior of HR in the absence of Beta-blocker in the early  and standard protocols Figure 4
Behavior of HR in the absence of Beta-blocker in the early 
and standard protocols.
Test result according to Beta-blocker for group C (standard  protocol) Figure 2
Test result according to Beta-blocker for group C (standard 
protocol).
Test result according to Beta-blocker for Group A & B (early  protocol) Figure 1
Test result according to Beta-blocker for Group A & B (early 
protocol). Behavior of HR during use of Beta-blocker in the early and  standard protocols Figure 3
Behavior of HR during use of Beta-blocker in the early and 
standard protocols.Cardiovascular Ultrasound 2006, 4:30 http://www.cardiovascularultrasound.com/content/4/1/30
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likely due to its protective effect on the induction of myo-
cardium ischemia.
In addition, the blood pressure response was higher in
patients who were on Beta-blocking therapy and did not
receive early atropine. Vatner et al.[22] also presented evi-
dence in which Beta-blockade caused substantial raise in
the arterial blood pressure and a slight increase in HR in
patients who used dobutamine. The authors believe that
this fact involves the combination of the vago barorecep-
tor activation and a direct blockade on chronotropism, as
well as the peripheral action of the drug which releases
alpha receptors [22]. Even though these drugs are
employed in the treatment for hypertension, they initially
Table 3: Descriptive analysis of ATR dose, test time, HR × SBP and DOB dose, according to Beta-blocker, for standard protocol 
(Group C).
Variables Beta n Mean p Value
ATR Dose No 30 0,38 ± 0,49 0,005
Yes 15 1,03 ± 0,80
Test time No 30 15,83 ± 3,55 0,024
Yes 15 18,73 ± 4,59
HR × SBP No 30 21566 ± 5445 0,028
Yes 15 17991 ± 3877
DOB Dose No 25 19 ± 4 0,089
Yes 11 25 ± 6
Behavior of SBP in the absence of Beta-blocker in the early  and standard protocols Figure 6
Behavior of SBP in the absence of Beta-blocker in the early 
and standard protocols.
Behavior of SBP during use of Beta-blocker in the early and  standard protocols Figure 5
Behavior of SBP during use of Beta-blocker in the early and 
standard protocols.
Table 2: Descriptive analysis of ATR dose, test time, HR × SBP and DOB dose, according to Beta-blocker, for Groups A + B (early 
protocol).
Variables Beta n Mean p Value
ATR Dose No 37 0,64 ± 0,37 0,0005
Yes 39 1,04 ± 0,54
Test time No 37 11,95 ± 2,88 0,010
Yes 39 13,77 ± 3,19
HR × SBP No 37 24674 ± 4308 0,008
Yes 39 21520 ± 5702
DOB Dose No 34 19 ± 4 0,055
Yes 37 23 ± 4Cardiovascular Ultrasound 2006, 4:30 http://www.cardiovascularultrasound.com/content/4/1/30
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cause an increase in the resistance of peripheral vessels.
The mechanism controlling hypertension is still not com-
pletely clear, but seems to result from the decrease in both
the cardiac output and the release of plasmatic Rennin [1].
In this review, the Beta-blocked group presented a lower
double product, a higher test time and a greater need for
atropine compared to those who were not taking similar
anti-ischemic therapy. Another significant finding was the
fact that more negative results occurred in patients who
were not Beta-blocked. The explanation for a greater
number of positive tests in Beta-blocked patients lies in
the higher probability of these patients suffering from
CAD leading to pharmacologic treatment. However, when
we analyze the groups receiving early atropine compared
to standard atropine administration, we observed that the
early administration of atropine optimized the hemody-
namic response of the Beta-blocked group, as well as
reduced test time and number of inconclusive results. The
chronotropic response exhibited a significant and evident
increase soon after initiating the administration of atro-
pine, which was maintained on an increasing scale up to
the end of test. Even though atropine did not completely
abolish the effects of the Beta-blockers, its addition
allowed for a more conclusive test, implying in a higher
possibility of inducing myocardial ischemia, a finding
also in agreement with the literature [19,23].
Furthermore we observed that the number of inconclusive
tests in Beta-blocked patients who were submitted to the
standard protocol was higher than in the early protocol
group. Other studies also confirm that the number of
inconclusive tests is due to the impossibility of obtaining
an adequate HR in these patients [24].
We have previously shown that adverse effects did not
increase in the early protocol [11] and others researches
demonstrated a lower incidence of arrhythmia and gen-
eral complications with the use of early protocol [25,26].
In the current analysis both time and hemodynamic
response were significantly improved with the early
administration of atropine. In the presence of an inhib-
ited hemodynamic response, patients with moderate or
significant coronary stenosis may not develop a new wall
abnormality. For this reason, if the level of plasmatic cat-
echolamine is already high at a dose of 20 or 30 μg/kg/
min [10] and HR does not rise at the same rate, simply
increasing infusion time of the drug would not lead to the
desired hemodynamic impact, and may imply a cost of
extra time.
In the group of Beta-blocked patients, the addition of
atropine should compensate the adrenergic blockade
effect by increasing HR, and what is more important,
increasing the sensitivity for the detection of myocardial
ischemia by the echocardiogram [7], thus equalizing the
test response.
Conclusion
Both the hemodynamic and chronotropic response dur-
ing DSE were pronouncedly decreased with the use of
Beta-blockers. Test time and the need for atropine were
higher than in the patients with no Beta-blockade. How-
ever, the early administration of atropine improved the
hemodynamic response and reduced test time in both
groups, with or without Beta-blockers, as well as the
number of inconclusive tests in the early protocol.
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